Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology

Journal of Viral Hepatitis

Volumn 15, Issue SUPPL.2, 2008, Pages 1-15

  Hendrickx, G ^a   Van Herck, K ^a,b   Vorsters, A ^a   Wiersma, S ^c   Shapiro, C ^d   Andrus, J K ^e   Ropero, A M ^e   Shouval, D ^f   Ward, W ^c   Van Damme, P ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b RESEARCH FOUNDATION FLANDERS FWO   (Belgium)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e PAN AMERICAN HEALTH ORGANIZATION   (United States)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Global hepatitis A meeting; Hepatitis A; Hepatitis A vaccination; Infectious disease control; Public health; Surveillance

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE;

CAUSE OF DEATH; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ENDEMIC DISEASE; EPIDEMIC; GROUPS BY AGE; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH SURVEY; HEPATITIS A; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MALE HOMOSEXUAL; MEDICAL DOCUMENTATION; MEDICAL EXPERT; MOLECULAR EPIDEMIOLOGY; MORTALITY; POLITICS; PRIORITY JOURNAL; SEROPREVALENCE; SOCIOECONOMICS; TRAVEL; VACCINATION;

ADULT; CHILD; EPIDEMIOLOGY, MOLECULAR; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; POPULATION SURVEILLANCE; RISK FACTORS; VACCINATION; WORLD HEALTH;

EID: 50649122763     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.01022.x     Document Type: Conference Paper

References (37)

1. Ferreira TC, Vieira SMG, Kieling CO, Silveira TR. Hepatitis A acute liver failure: follow up of paediatric patients in southern Brazil. J Virol Hepat 2008 15 (Suppl 2 66 68.
2. Shah U, Habib Z, Kleinman RE. Liver failure attributable to hepatitis A virus infection in a developing country. Pediatrics 2000 105 (2 436 438.
3. Xu ZY, Wang XX, Liu CQ, Li YT, Zhuang FC. Decline of the risk of hepatitis A in China: a country with a booming economy and changing life styles. J Virol Hepat 2008 15 (Suppl 2 33 37.
4. Shliakhtenko L, Plotnikova V, Levakova I, Rubis L, Solovieva E, Mukomolov S. Modern epidemiology of Hepatitis A in the North Western region of the Russian Federation. J Virol Hepat 2008 15 (Suppl 2 38 42.
5. Vitral CL, Souto FJD, Gaspar AMC. Shifting epidemiology of hepatitis A in Brazil: Should we think about immunization policy? J Virol Hepat 2008 15 (Suppl 2 22 25.
6. Moisseeva A, Marichev K, Biloschitchkay NA et al. Hepatitis A sero-prevalence in the Ukraine. J Virol Hepat 2008 15 (Suppl 2 43 46.
7. Zhou F, Shefer A, Weinbaum C, McCauley M, Kong Y. Impact of hepatitis A vaccination on health care utilization in the United States, 1996-2004. Vaccine 2007 25 (18 3581 3587.
8. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005 294 : 202 210.
9. Tosti ME, Spada E, Romano L, Zanetti A, Mélé A. Acute hepatitis A in Italy: incidence of risk factors and preventative measures. J Virol Hepat 2008 15 (Suppl 2 26 32.
10. WHO. Vaccine Introduction Guidelines. Adding a Vaccine to a National Immunization Programme: Decision and Implementation. 2005. WHO/IVB/05.18. http://www.who.int/vaccines-documents [accessed on 25 May 2008].
11. Ambrosch F, Finkel B, Herzog C, Koren A, Kollaritsch H. Rapid antibody response after vaccination with a virosomal hepatitis a vaccine. Infection 2004; 32(3): 149-52. Erratum in : Infection 2004 32 (4 249.
12. Connor BA, Van Herck K, Van Damme P. Rapid protection and vaccination against hepatitis A for travellers. BioDrugs 2003 17 (Suppl. 1 19 21.
13. Vidor E, Dumas R, Porteret V, Bailleux F, Veitch K. Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data. Eur J Clin Microbiol Infect Dis 2004 23 (4 300 309.
14. Rendi-Wagner P, Korinek M, Winkler B, Kundi M, Kollaritsch H, Wiedermann U. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine 2007 5 : 927 931.
15. Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 2001 63 (1 1 7.
16. Bovier PA, Bock J, Loutan L, Farinelli T, Glueck R, Herzog C. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol 2002 68 (4 489 493.
17. Van Herck K, Van Damme P, Lievens M, Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol 2004 72 (2 194 196.
18. Van Damme P, Banatvala J, Fay O et al. International Consensus Group on Hepatitis A Virus Immunity. Hepatitis A booster vaccination: is there a need? Lancet 2003 362 (9389 1065 1071.
19. Beck BR, Hatz C, Brönnimann R, Herzog C. Successful booster antibody response up to 54 months after single primary vaccination with virosome-formulated, aluminum-free hepatitis A vaccine. Clin Infect Dis 2003 37 (9 e126 e128.
20. Iwarson S, Lindh M, Widerström L. Excellent booster response 4-6 y after a single primary dose of an inactivated hepatitis A vaccine. Scand J Infect Dis 2002 34 (2 110 111.
21. Orr N, Klement E, Gillis D et al. Long-term immunity in young adults after a single dose of inactivated hepatitis A vaccines. Vaccine 2006 24 (20 4328 4332.
22. Williams JL, Bruden DA, Cagle HH et al. Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. Vaccine 2003 21 (23 3208 3211.
23. Van Damme P, Van Herck K. Editorials: Effect of Hepatitis A Vaccination Programs. JAMA 2005 294 : 246 248.
24. Mutsch M, Masserey V, Gut C, Steffen R. Hepatitis A virus infections in travelers 1988-2004. Clin Infect Dis 2006 42 : 490 497.
25. WHO. Annual brochure on International Travel and Health. 2007. http://www.who.int/ith [accessed on 25 May 2008 C, Thiede H, Perdue T et al. Seattle Young Men's Survey Team. Viral hepatitis among young men who have sex with men: prevalence of infection, risk behaviors, and vaccination. Sex Transm Dis 2003 30 (5 425 432.
26. Tedaldi EM, Baker RK, Moorman AC et al. HIV Outpatient Study (HOPS) Investigators. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 2004 10 : 1478 1484.
27. Gerlich M, Gschwend P, Uchtenhagen A, Krämer A, Rehm J. Prevalence of hepatitis and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994 and 2002. Eur J Epidemiol 2006 21 (7 545 549.
28. Public Health Reports 2007 122 (Suppl. 2). Available at: http://www.publichealthreports.org/archives/issuecontents.cfm? Volume-122&Issue-8 (accessed 12 July 2008)
29. Victor JC, Monto AS, Surdina TY et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 2007 357 : 1685.
30. Beutels P, Edmunds WJ, Antoñanzas F et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. PharmacoEconomics 2002 20 (1 1 7.
31. Anonychuk AM, Tricco AC, Bauch CT et al. Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies. Pharmacoeconomics 2008 26 (1 17 32.
32. Armstrong GL, Billah K, Rein DB, Hicks KA, Wirth KE, Bell BP. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity. Pediatrics 2007 119 (1 e22 e29.
33. Lopez E, Debbag R, Coudeville L, Baron-Papillon F, Armoni J. The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis. J Gastroenterol 2007 42 (2 152 160.
34. Bauch CT, Anonychuk AM, Pham BZ, Gilca V, Duval B, Krahn MD. Cost-utility of universal hepatitis A vaccination in Canada. Vaccine 2007 51 : 8536 8548.
35. Van Effelterre TP, Zink TK, Hoet BJ, Hausdorff WP, Rosenthal P. A mathematical model of hepatitis a transmission in the United States indicates value of universal childhood immunization. Clin Infect Dis 2006 43 (2 158 164.
36. Andrus JK, Toscano C, Lewis M et al. A model for enhancing evidenced-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac Initiative. Public Health Rep 2007 122 (6 811 816.
37. GAVI. Vaccine Investment Strategy (GAVI Alliance Fund Board Meeting 11-12 May 2007). http://www.gavialliance.org/resources/Vaccine_Investment_Strategy. pdf [accessed on 25 May 2008].